Provenance Record

Strong 1,147-word News piece with a well-structured four-section layout (Overview, What We Know, What We Don't Know, Analysis). Every factual claim is inline-cited to a specific source URL. The 'What We Don't Know' and 'Analysis' sections demonstrate genuine editorial value, raising legitimate scientific uncertainties about AAV durability, intrapancreatic delivery risks, and the multifactorial nature of T2D. Word count is well within News range (400–1,200). No sensationalism or AI self-reference detected.

Four sources cited. Source 0 (GlobeNewswire, HTTP 200): Primary press release verified in full — confirms RJVA-001, May 11, 2026 authorization, Netherlands CTA, AAV mechanism, endoscopic ultrasound delivery, three escalating dose cohorts of 3 participants, ages 35–70, HbA1c 7.0–10.0%, BMI 27–40, CEO Harith Rajagopalan MD PhD, PI Prof. Jacques Bergman M.D. Ph.D. (Professor of Gastrointestinal Endoscopy and Deputy Chair, Gastroenterology & Hepatology at Amsterdam UMC), Nasdaq: GUTS, H2 2026 first-patient target, Australia CTA submitted (Q3 2026 feedback expected), US preclinical/no IND. Source 1 (BioSpace, HTTP 200): Mirror of the press release — all key facts corroborated. Source 2 (ClinicalTrialsArena via Archive.org, HTTP 200): Independently confirms Netherlands authorization, Australia Q3 2026 regulatory feedback, US preclinical/no IND, trial design, GLP-1 washout, endoscopic delivery, Rajagopalan quote. Source 3 (Drug Discovery World, HTTP 403 — blocked): Not snapshot-archived. The article uses DDW only for one claim in the Analysis section ('Drug Discovery World noted the IND has not been filed in the US'), which is independently corroborated by sources 0 and 2. No unique claim relies solely on DDW. allowlist warnings for clinicaltrialsarena.com and ddw-online.com — both are recognized specialist industry publications; recommend adding to allowlist.

All verifiable biotech-specific claims confirmed against snapshots: authorization date May 11, 2026 (confirmed); Dutch/Netherlands regulator (confirmed — article body correctly says 'Dutch regulators', title uses 'European' which is technically broader but not incorrect since the Netherlands CTA is an EU-framework authorization); RJVA-001 drug name (confirmed); AAV-based and endoscopic ultrasound-guided delivery (confirmed); 3 escalating cohorts × 3 participants + optional expansion of up to 20 (confirmed); inclusion criteria ages 35–70, HbA1c 7.0–10.0%, BMI 27–40 (confirmed); CEO spelling Harith Rajagopalan, MD PhD (confirmed); PI spelling Prof. Jacques Bergman, M.D., Ph.D. (confirmed); Nasdaq: GUTS (confirmed); Australia Q3 2026, US preclinical/no IND (confirmed); RJVA-002 dual GIP/GLP-1 in preclinical (confirmed). No fabricated quotes — all quoted text traces exactly to the press release. Minor note: the title says 'European Clearance' while the body more precisely says 'Dutch regulators' — not a factual error, the Netherlands CTA is an EU-framework authorization, but the title is slightly imprecise relative to the source headline ('in the Netherlands').

High-quality biotech news article. All major facts verified against snapshots from the primary press release and two independent publications. Sources are appropriate for a Phase 1/2 clinical trial authorization story. The DDW source access failure is minor — the claim it supports is independently corroborated. Approve with corrections to source allowlist.